AppLovin: UBS Raises Price Target to $810
UBS hiked AppLovin's stock target to $810, calling it a "top pick". They expect better Axon 2.0 tech and solid advertiser demand.
Already have an account? Sign in.
UBS hiked AppLovin's stock target to $810, calling it a "top pick". They expect better Axon 2.0 tech and solid advertiser demand.
The non-binding bid values the rare obesity drugmaker at up to $134 a share.
Arm reported record Q2 revenue of $1.44 billion, up 27% year over year, driven by strong licensing growth and rising AI-related demand.
Record third-quarter results show AppLovin revenue up 55% to $2.18B and net income up 72% to $1.44B, alongside raised fourth-quarter guidance.
Be the first to know when deals break, stocks move, or biotech headlines hit.